Results 191 to 200 of about 119,295 (311)

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell-cycle, MAPK, and PI3K pathways. [PDF]

J Pathol
Monti M, Romanello MB, Agnelli L, Orlandi M, Bertoli L, Picinoli S, Pezzali I, Mandelli GE, Medicina D, Ribaudo G, Busico A, Conca E, Pellegrini V, Balzarini P, Gallucci D, Di Matteo A, Lombardi D, Ghigna C, Pruneri G, Gianoncelli A, Rossato M, Vermi W.   +21 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review. [PDF]

Neuropathology
Bauluz L, Marcos-González S, Castanedo D, Velásquez C.   +3 more
europepmc   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

A simple four-variable nomogram integrating age, ACR-TIRADS, BRAF V600E and Bethesda cytology for predicting occult central lymph node metastasis in papillary thyroid microcarcinoma: a preoperative risk-stratification tool. [PDF]

Gland Surg
Cao B, Fei G, Zhou SC, Ding Y, Liu L.
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment. [PDF]

J Transl Med
Ahmadi S, Hoseini M, Ravari MS, Zarei M, Shahrokhi P, Mousavi P.   +5 more
europepmc   +1 more source

Iterations of BRAF [PDF]

Nature Reviews Cancer, 2012
openaire   +1 more source

Pure erythroid leukaemia in early infancy: Diagnostic pitfalls and clinical challenges

British Journal of Haematology, EarlyView.
Riccardo De Carli, Baptiste Le Calvez, Elodie Lainey, Catherine Settegrana, Marion Strullu, Marlene Pouthier   +5 more
wiley   +1 more source

Papillary craniopharyngioma following an initial diagnosis of Rathke cleft cyst: a case report and narrative review. [PDF]

JCEM Case Rep
Caputo C, McKelvie PA, Dhillon R, Smith PD.   +3 more
europepmc   +1 more source